Burke, M.Morais, C.Oliver, K.Lambie, D.Gobe, G.Carroll, R.Staatz, C.Sinnya, S.Soyer, H.Winterford, C.Haass, N.Campbell, S.Isbel, N.2015-04-282015-04-282015American Journal of Clinical Pathology, 2015; 143(4):514-5260002-91731943-7722http://hdl.handle.net/2440/90731Objectives: This study aims to investigate how immunosuppression influences the protein expression of antiapoptotic members of the Bcl-2 family—namely, Bcl-xL and Mcl-1—in nonmelanoma skin cancer (NMSC) and the peritumoral epidermis of renal transplant recipients. Methods: NMSC and peritumoral epidermis protein expression of Bcl-xL and Mcl-1 were assessed by immunohistochemistry in renal transplant recipients receiving tacrolimus or sirolimus and the general population not receiving immunosuppression. Results: NMSC from renal transplant recipients compared with patients not receiving immunosuppressant medications had a reduced Bcl-xL expression intensity (P = .042). Mcl-1 expression intensity in NMSC was decreased in tacrolimus-treated patients compared with sirolimus-treated patients and the nonimmunosuppressed population (P = .024). Bcl-xL expression intensity was increased in peritumoral epidermis compared with NMSC (P = .002). Conclusions: It was shown for the first time that Bcl-xL and Mcl-1 expression are widespread in the peritumoral epidermis and NMSC of renal transplant recipients. Importantly in NMSC, Bcl-xL expression was reduced with immunosuppression exposure, and Mcl-1 expression was reduced in tacrolimus-treated compared with sirolimustreated patients.en© 2015 by The American Society for Clinical PathologyHumansCarcinoma, Basal CellCarcinoma, Squamous CellSkin NeoplasmsSirolimusTacrolimusImmunosuppressive AgentsKidney TransplantationImmunohistochemistryMitosisApoptosisAdultAgedAged, 80 and overMiddle AgedFemaleMalebcl-X ProteinMyeloid Cell Leukemia Sequence 1 ProteinTransplant RecipientsJournal article003002509810.1309/AJCPQNB5WA3PLQBK0003513312000082-s2.0-84930337119178279Carroll, R. [0000-0002-6238-026X]